Allogeneic hematopoietic stem cell transplantation for pediatric acute leukemia harboring the PICALM-MLLT10 fusion in two cases

Yu CHEN, Yong-Bing ZHU, Jia-Si ZHANG, Ai ZHANG, Ya-Qin WANG, Qun HU, Ai-Guo LIU

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (11) : 1414-1419.

PDF(605 KB)
HTML
PDF(605 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (11) : 1414-1419. DOI: 10.7499/j.issn.1008-8830.2503092
CLINICAL EXPERIENCE

Allogeneic hematopoietic stem cell transplantation for pediatric acute leukemia harboring the PICALM-MLLT10 fusion in two cases

Author information +
History +

Abstract

A retrospective analysis was conducted on the clinical course of two children with PICALM-MLLT10-positive acute leukemia treated at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, between July 2021 and July 2023. The patients were diagnosed with acute T-lymphoblastic leukemia with central nervous system involvement and high-risk acute myeloid leukemia, respectively. Both achieved bone marrow complete remission after conventional chemotherapy combined with venetoclax. Following conversion to molecular negativity, they underwent sequential allogeneic hematopoietic stem cell transplantation. At the latest follow-up, both patients were alive and in good clinical condition. These observations suggest that proceeding to hematopoietic stem cell transplantation after venetoclax-based chemotherapy may improve the long-term survival of children with PICALM-MLLT10-positive leukemia.

Key words

Acute leukemia / PICALM-MLLT10 / Hematopoietic stem cell transplantation / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Yu CHEN , Yong-Bing ZHU , Jia-Si ZHANG , et al . Allogeneic hematopoietic stem cell transplantation for pediatric acute leukemia harboring the PICALM-MLLT10 fusion in two cases[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(11): 1414-1419 https://doi.org/10.7499/j.issn.1008-8830.2503092

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
[1]
Caudell D, Aplan PD. The role of CALM-AF10 gene fusion in acute leukemia[J]. Leukemia, 2008, 22(4): 678-685. PMCID: PMC2366104. DOI: 10.1038/sj.leu.2405074 .
https://www.ncbi.nlm.nih.gov/pubmed/18094714
Cited in this article [7]
[2]
Anon. t(10;11)(p13-14;q14-21): a new recurrent translocation in T-cell acute lymphoblastic leukemias. Groupe Français de Cytogénétique Hématologique (GFCH)[J]. Genes Chromosomes Cancer, 1991, 3(6): 411-415.
https://www.ncbi.nlm.nih.gov/pubmed/1777411
Cited in this article [2]
[3]
Asnafi V, Radford-Weiss I, Dastugue N, et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage[J]. Blood, 2003, 102(3): 1000-1006. DOI: 10.1182/blood-2002-09-2913 .
https://www.ncbi.nlm.nih.gov/pubmed/12676784
Cited in this article [2]
[4]
Mark C, Meshinchi S, Joyce B, et al. Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias[J]. Br J Haematol, 2024, 204(2): 576-584. DOI: 10.1111/bjh.19067 .
https://www.ncbi.nlm.nih.gov/pubmed/37743097
Cited in this article [5]
[5]
Borel C, Dastugue N, Cances-Lauwers V, et al. PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients[J]. Leuk Res, 2012, 36(11): 1365-1369. DOI: 10.1016/j.leukres.2012.07.008 .
https://www.ncbi.nlm.nih.gov/pubmed/22871473
Cited in this article [1]
[6]
Abla O, Ries RE, Triche T, et al. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia[J]. Blood Adv, 2024, 8(8): 2005-2017. PMCID: PMC11024924. DOI: 10.1182/bloodadvances.2023010805 .
https://www.ncbi.nlm.nih.gov/pubmed/38306602
Cited in this article [1]
[7]
Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic[J]. Mol Biol Cell, 1999, 10(8): 2687-2702. PMCID: PMC25500. DOI: 10.1091/mbc.10.8.2687 .
https://www.ncbi.nlm.nih.gov/pubmed/10436022
Cited in this article [1]
[8]
Ben Abdelali R, Asnafi V, Petit A, et al. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest[J]. Haematologica, 2013, 98(11): 1711-1717. PMCID: PMC3815171. DOI: 10.3324/haematol.2013.086082 .
https://www.ncbi.nlm.nih.gov/pubmed/23831922
Cited in this article [1]
[9]
Yu H, Du Y, Xu J, et al. Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma[J]. Transl Cancer Res, 2019, 8(6): 2485-2495. PMCID: PMC8797845. DOI: 10.21037/tcr.2019.10.04 .
https://www.ncbi.nlm.nih.gov/pubmed/35117001
Cited in this article [1]
[10]
Wang J, Zhang W, Xu X, et al. Clinicopathologic features and outcomes of acute leukemia harboring PICALM::MLLT10 fusion[J]. Hum Pathol, 2024, 151: 105626. DOI: 10.1016/j.humpath.2024.07.003 .
https://www.ncbi.nlm.nih.gov/pubmed/38971327
Cited in this article [2]
[11]
鲁淑婷, 姚金红, 李少阳, 等. 伴PICALM-MLLT10的急性非淋巴细胞白血病2例报告并文献复习[J]. 重庆医学, 2021, 50(19): 3369-3374. DOI: 10.3969/j.issn.1671-8348.2021.19.028 .
Cited in this article [2]
[12]
胡德媛, 沈凯, 郭虞莎, 等. PICAML-MLLT10融合基因阳性急性髓系白血病4例报告并文献复习[J]. 中华血液学杂志, 2023, 44(8): 687-689. PMCID: PMC10520228. DOI: 10.3760/cma.j.issn.0253-2727.2023.08.014 .
https://www.ncbi.nlm.nih.gov/pubmed/37803846
Cited in this article [1]
[13]
Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study[J]. Lancet Oncol, 2020, 21(4): 551-560. PMCID: PMC7153631. DOI: 10.1016/S1470-2045(20)30060-7 .
https://www.ncbi.nlm.nih.gov/pubmed/32171069
Cited in this article [1]
[14]
Luskin MR, Shimony S, Keating J, et al. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia[J]. Blood Adv, 2025, 9(3): 617-626. PMCID: PMC11847096. DOI: 10.1182/bloodadvances.2024014405 .
https://www.ncbi.nlm.nih.gov/pubmed/39546748
Cited in this article [1]
[15]
Sun H, Zhu Y, Li J, et al. PICALM::MLLT10 may indicate a new subgroup of acute leukemias with miscellaneous immunophenotype and poor initial treatment response but showing sensitivity to venetoclax[J]. EJHaem, 2024, 5(3): 565-572. PMCID: PMC11182389. DOI: 10.1002/jha2.922 .
https://www.ncbi.nlm.nih.gov/pubmed/38895061
Cited in this article [1]
[16]
Jiang Y, Ji L, Jin X, et al. Case report: treatment of two cases of recurrent/refractory early T-cell precursor acute lymphoblastic leukemia with venetoclax combined with the CAG regimen[J]. Front Med (Lausanne), 2024, 11: 1358161. PMCID: PMC10957540. DOI: 10.3389/fmed.2024.1358161 .
https://www.ncbi.nlm.nih.gov/pubmed/38523911
Cited in this article [1]
[17]
Yiğit Kaya S, Bektas S, Askin AE, et al. Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient[J]. Ann Hematol, 2023, 102(6): 1599-1600. DOI: 10.1007/s00277-023-05231-4 .
https://www.ncbi.nlm.nih.gov/pubmed/37099080
[18]
DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia[J]. J Clin Oncol, 2021, 39(25): 2768-2778. PMCID: PMC8407653. DOI: 10.1200/JCO.20.03736 .
https://www.ncbi.nlm.nih.gov/pubmed/34043428
Cited in this article [1]
[19]
Daver NG, Maiti A, Kadia TM, et al. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions[J]. Cancer Discov, 2022, 12(11): 2516-2529. PMCID: PMC9627130. DOI: 10.1158/2159-8290.CD-22-0332 .
https://www.ncbi.nlm.nih.gov/pubmed/36218325
Cited in this article [1]
[20]
Cheng CK, Yung YL, Chan HY, et al. Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia[J]. Commun Biol, 2023, 6(1): 356. PMCID: PMC10066286. DOI: 10.1038/s42003-023-04732-2 .
https://www.ncbi.nlm.nih.gov/pubmed/37002311
Cited in this article [1]
[21]
Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia[J]. Blood, 2018, 131(24): 2661-2669. PMCID: PMC6265654. DOI: 10.1182/blood-2017-12-818948 .
https://www.ncbi.nlm.nih.gov/pubmed/29724899
Cited in this article [1]
[22]
Shukla N, Wetmore C, O'Brien MM, et al. Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia[J]. Blood, 2016, 128(22): 2780. DOI: 10.1182/blood.V128.22.2780.2780 .
Cited in this article [1]
[23]
Miao H, Kim E, Chen D, et al. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations[J]. Blood, 2020, 136(25): 2958-2963. PMCID: PMC7751359. DOI: 10.1182/blood.2020006575 .
https://www.ncbi.nlm.nih.gov/pubmed/33331926
Cited in this article [1]

Footnotes

所有作者均声明无利益冲突。

PDF(605 KB)
HTML

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉